參考文獻/References:
[1] COLE ZA,DENNISON EM,COOPER C.Osteoporosis epidemiology update[J].Curr Rheumatol Rep,2008,10(2):92-96.
[2] 陳林,程軍,李波,等.渝東北地區(qū)老年人骨質(zhì)疏松流行病學(xué)調(diào)查[J].中國骨質(zhì)疏松雜志,2016,22(8):1050-1052.
[3] 劉峰.骨質(zhì)疏松流行病學(xué)及防治研究進展[J].醫(yī)學(xué)理論與實踐,2017,30(22):3321-3322.
[4] 韓亞軍,帖小佳,伊力哈木·托合提.中國中老年人骨質(zhì)疏松癥患病率的Meta分析[J].中國組織工程研究,2014,18(7):1129-1134.
[5] 喬芳,常靜.骨質(zhì)疏松流行病學(xué)調(diào)查分析[J].中國實用醫(yī)藥,2012,7(30):271-272.
[6] QIN J,LI R,RAES J,et al.A human gut microbial gene catalogue established by metagenomic sequencing[J].Nature,2010,464(7285):59-65.
[7] VITAL M,HOWE AC,TIEDJE JM.Revealing the bacterial butyrate synthesis pathways by analyzing(meta)genomic data[J].MBio,2014,5(2):889.
[8] FRANSEN F,VAN BEEK AA,BORGHUIS T,et al.Aged Gut Microbiota Contributes to Systemical Inflammaging after Transfer to Germ-Free Mice[J].Front Immunol,2017,8:1385.
[9] LERNER A,NEIDHÖFER S,MATTHIAS T.The Gut Microbiome Feelings of the Brain:A Perspective for Non-Microbiologists[J].Microorganisms,2017,5(4):66.
[10] LAHTI L,SALOJÄRVI J,SALONEN A,et al.Tipping elements in the human intestinal ecosystem[J].Nat Commun,2014,5:4344.
[11] OHLSSON C,ENGDAHL C,FÄK F,et al.Probiotics protect mice from ovariectomy-induced cortical bone loss[J].PLoS One,2014,9(3):92368.
[12] NOVINCE CM,WHITTOW CR,AARTUN JD,et al.Commensal Gut Microbiota Immunomodulatory Actions in Bone Marrow and Liver have Catabolic Effects on Skeletal Homeostasis in Health[J].Sci Rep,2017,7(1):5747.
[13] CHUNG HJ,KYUNG KIM W,JOO PARK H,et al.Anti-osteoporotic activity of harpagide by regulation of bone formation in osteoblast cell culture and ovariectomy-induced bone loss mouse models[J].J Ethnopharmacol,2016,179:66-75.
[14] BUCHET R,MILLÁN JL,MAGNE D.Multisystemic functions of alkaline phosphatases[J].Methods Mol Biol,2013,1053:27-51.
[15] CHEN YC,GREENBAUM J,SHEN H,et al.Association Between Gut Microbiota and Bone Health:Potential Mechanisms and Prospective[J].J Clin Endocrinol Metab,2017,102(10):3635-3646.
[16] EJTAHED HS,SOROUSH AR,ANGOORANI P,et al.Gut Microbiota as a Target in the Pathogenesis of Metabolic Disorders:A New Approach to Novel Therapeutic Agents[J].Horm Metab Res,2016,48(6):349-358.
[17] MCCABE L,BRITTON RA,PARAMESWARAN N.Prebiotic and Probiotic Regulation of Bone Health:Role of the Intestine and its Microbiome[J].Curr Osteoporos Rep,2015,13(6):363-371.
[18] KWAN TAT S,PADRINES M,THÉOLEYRE S,et al.IL-6,RANKL,TNF-alpha/IL-1:interrelations in bone resorption pathophysiology[J].Cytokine Growth Factor Rev,2004,15(1):49-60.
[19] KANIS JA,MCCLOSKEY EV,JOHANSSON H,et al.European guidance for the diagnosis and management of osteoporosis in postmenopausal women[J].Osteoporos Int,2013,24(1):23-57.
[20] GÓMEZ NAVARRO R.Use of the FRAX algorithm to calculate the fracture risk in women of a rural area[J].Rev Esp Salud Publica,2010,84(3):321-330.
[21] LEKAMWASAM S,ADACHI JD,AGNUSDEI D,et al.A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis[J].Osteoporos Int,2012,23(9):2257-2276.
[22] 周年,劉波,徐彭.氧化應(yīng)激與骨質(zhì)疏松癥的研究進展[J].中國骨質(zhì)疏松雜志,2014,20(12):1485-1489.
[23] 張鯤,陳曉亮.氧化應(yīng)激與骨質(zhì)疏松[J].中國骨質(zhì)疏松雜志,2006,12(5):535-537.
[24] CHAPPLE SJ,PUSZYK WM,MANN GE.Keap1-Nrf2 regulated redox signaling in utero:Priming of disease susceptibility in offspring[J].Free Radic Biol Med,2015,88(Pt B):212-220.
[25] AGARWAL A,APONTE-MELLADO A,PREMKUMAR BJ,et al.The effects of oxidative stress on female reproduction:a review[J].Reprod Biol Endocrinol,2012,10:49.
[26] MANOLAGAS SC.From estrogen-centric to aging and oxidative stress:a revised perspective of the pathogenesis of osteoporosis[J].Endocr Rev,2010,31(3):266-300.
[27] PANSINI F,MOLLICA G,BERGAMINI CM.Management of the menopausal disturbances and oxidative stress[J].Curr Pharm Des,2005,11(16):2063-2073.
[28] LEAN JM,DAVIES JT,FULLER K,et al.A crucial role for thiol antioxidants in estrogen-deficiency bone loss[J].J Clin Invest,2003,112(6):915-923.
[29] MEDEMA RH,KOPS GJ,BOS JL,et al.AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1[J].Nature,2000,404(6779):782-787.
中醫(yī)正骨2018年3月第30卷第3期 J Trad Chin Orthop Trauma,2018,Vol.30,No.3(總215)
(總216)中醫(yī)正骨2018年3月第30卷第3期 J Trad Chin Orthop Trauma,2018,Vol.30,No.3
[30] TRAN H,BRUNET A,GRENIER JM,et al.DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein[J].Science,2002,296(5567):530-534.
[31] KOPS GJ,DANSEN TB,POLDERMAN PE,et al.Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress[J].Nature,2002,419(6904):316-321.
[32] VILLATE O,TURATSINZE JV,MASCALI LG,et al.Nova1 is a master regulator of alternative splicing in pancreatic beta cells[J].Nucleic Acids Res,2014,42(18):11818-11830.
[33] BRUNET A,BONNI A,ZIGMOND MJ,et al.Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor[J].Cell,1999,96(6):857-868.
[34] POLVANI S,TAROCCHI M,GALLI A.PPARγ and Oxidative Stress:Con(β)Catenating NRF2 and FOXO[J].PPAR Res,2012,2012:641087.
[35] HOOGEBOOM D,ESSERS MA,POLDERMAN PE,et al.Interaction of FOXO with beta-catenin inhibits beta-catenin/T cell factor activity[J].J Biol Chem,2008,283(14):9224-9230.
[36] POUYET L,CARRIER A.Mutant mouse models of oxidative stress[J].Transgenic Res,2010,19(2):155-164.
[37] ESSERS MA,DE VRIES-SMITS LM,BARKER N,et al.Functional interaction between beta-catenin and FOXO in oxidative stress signaling[J].Science,2005,308(5725):1181-1184.
[38] HOOGEBOOM D,BURGERING BM.Should I stay or should I go:beta-catenin decides under stress[J].Biochim Biophys Acta,2009,1796(2):63-74.
[39] ALMEIDA M.Unraveling the role of FoxOs in bone—insights from mouse models[J].Bone,2011,49(3):319-327.
[40] ALMEIDA M,HAN L,AMBROGINI E,et al.Glucocorticoids and tumor necrosis factor α increase oxidative stress and suppress Wnt protein signaling in osteoblasts[J].J Biol Chem,2011,286(52):44326-44335.
[41] OH J,HUR MW,LEE CE.SOCS1 protects protein tyrosine phosphatases by thioredoxin upregulation and attenuates Jaks to suppress ROS-mediated apoptosis[J].Oncogene,2009,28(35):3145-3156.
[42] KUANG W,ZHENG L,XU X,et al.Dysregulation of the miR-146a-Smad4 axis impairs osteogenesis of bone mesenchymal stem cells under inflammation[J].Bone Res,2017,5:17037.
[43] KIM HK,LEE JS,KIM JH,et al.Bone-forming peptide-2 derived from BMP-7 enhances osteoblast differentiation from multipotent bone marrow stromal cells and bone formation[J].Exp Mol Med,2017,49(5):328.
[44] BALANI DH,ONO N,KRONENBERG HM.Parathyroid hormone regulates fates of murine osteoblast precursors in vivo[J].J Clin Invest,2017,127(9):3327-3338.
[45] VAN DE PEPPEL J,STRINI T,TILBURG J,et al.Identification of Three Early Phases of Cell-Fate Determination during Osteogenic and Adipogenic Differentiation by Transcription Factor Dynamics[J].Stem Cell Reports,2017,8(4):947-960.
[46] ZHOU BO,YU H,YUE R,et al.Bone marrow adipocytes promote the regeneration of stem cells and haematopoiesis by secreting SCF[J].Nat Cell Biol,2017,19(8):891-903.
[47] WU M,WANG Y,SHAO JZ,et al.Cbfβ governs osteoblast-adipocyte lineage commitment through enhancing β-catenin signaling and suppressing adipogenesis gene expression[J].Proc Natl Acad Sci USA,2017,114(38):10119-10124.
[48] DEBRUINE ZJ,XU HE,MELCHER K.Assembly and architecture of the Wnt/β-catenin signalosome at the membrane[J].Br J Pharmacol,2017,174(24):4564-4574.
[49] DEBRUINE ZJ,KE J,HARIKUMAR KG,et al.Wnt5a promotes Frizzled-4 signalosome assembly by stabilizing cysteine-rich domain dimerization[J].Genes Dev,2017,31(9):916-926.
[50] YANG N,LI Y,WANG G,et al.Tumor necrosis factor-α suppresses adipogenic and osteogenic differentiation of human periodontal ligament stem cell by inhibiting miR-21/Spry1 functional axis[J].Differentiation,2017,97:33-43.
[51] ZHANG L,TANG Y,ZHU X,et al.Overexpression of MiR-335-5p Promotes Bone Formation and Regeneration in Mice[J].J Bone Miner Res,2017,32(12):2466-2475.
[52] ANASTASILAKIS AD,POLYZOS SA,MAKRAS P,et al.Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass:the 3-month effect of zoledronic acid,denosumab or teriparatide treatment[J].Expert Opin Ther Targets,2015,19(3):299-306.
[53] ZHANG Y,FENG E,XU Y,et al.Serum Sema4D levels are associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis[J].Int J Clin Exp Med,2015,8(9):16352-16357.
[54] 張韜,陳冬冬,翁艷,等.Sema4D基因沉默對骨髓間充質(zhì)干細胞成骨及成脂肪分化相關(guān)基因表達的影響[J].廈門大學(xué)學(xué)報(自然科學(xué)版),2017,56(2):173-177.
[55] 李冠彗,李燦東,李西海,等.雌激素調(diào)控絕經(jīng)后骨質(zhì)疏松癥骨吸收-骨形成耦聯(lián)失衡的機制[J].中醫(yī)正骨,2016,28(2):36-40.
相似文獻/References:
[1]李林軍.應(yīng)用膨脹式椎弓根螺釘內(nèi)固定治療合并骨質(zhì)疏松的
胸腰椎退行性疾病[J].中醫(yī)正骨,2015,27(08):49.
[2]李學(xué)朋,朱立國.骨疏康膠囊對去卵巢大鼠骨小梁的影響[J].中醫(yī)正骨,2015,27(12):12.
LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康膠囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(03):12.
[3]陳冠軍,陳揚,莊汝杰.可灌注骨水泥椎弓根螺釘系統(tǒng)
在老年腰椎疾患手術(shù)中的應(yīng)用[J].中醫(yī)正骨,2015,27(02):40.
[4]王丹輝,賁越,韓梅.林蛙油治療絕經(jīng)后骨質(zhì)疏松癥的臨床研究[J].中醫(yī)正骨,2014,26(01):27.
Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(03):27.
[5]黃建華,黃建武,李慧輝,等.加味左歸丸對絕經(jīng)后骨質(zhì)疏松癥肝腎不足證
患者骨密度的影響[J].中醫(yī)正骨,2013,25(11):19.
Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(03):19.
[6]項旻,楊虹,林愛菊,等.絕經(jīng)后2型糖尿病患者骨質(zhì)疏松與血微量元素的關(guān)系研究[J].中醫(yī)正骨,2013,25(12):20.
Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(03):20.
[7]史曉林,李春雯,張志強.弱陽離子磁珠分離技術(shù)和基質(zhì)輔助激光解吸電離飛行時間質(zhì)譜技術(shù)在原發(fā)性Ⅰ型骨質(zhì)疏松癥血清標志蛋白篩選中的應(yīng)用[J].中醫(yī)正骨,2014,26(03):5.
Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(03):5.
[8]李明,徐明雄,馮左基,等.自擬壯骨方治療絕經(jīng)后骨質(zhì)疏松癥的療效及作用機制研究[J].中醫(yī)正骨,2014,26(09):21.
Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(03):21.
[9]陳俊杰,李晴晴,夏瑢.脂代謝及血清內(nèi)脂素水平與絕經(jīng)后骨質(zhì)疏松癥的
相關(guān)性研究[J].中醫(yī)正骨,2012,24(04):16.
CHEN Jun-jie*,LI Qing-qing,XIA Rong.*.Study on the correlations between the levels of lipid metabolism and serum visfatin and postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(03):16.
[10]許超,肖魯偉,吳承亮.絕經(jīng)后女性骨質(zhì)疏松癥辨證分型與抑郁焦慮的關(guān)系研究[J].中醫(yī)正骨,2011,23(12):3.
XU Chao*,XIAO Lu-wei,WU Cheng-liang.*.Study on the relationship between the syndrome differ classification and the depression and anxiety for the postmenopausal women with osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2011,23(03):3.
[11]韓艷,溫利平,劉娜,等.補腎活血方對去卵巢大鼠骨代謝及骨密度的影響[J].中醫(yī)正骨,2015,27(12):7.
HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(補腎活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(03):7.
[12]歐國峰,劉鑫,董博,等.絕經(jīng)后骨質(zhì)疏松癥的免疫學(xué)研究進展[J].中醫(yī)正骨,2016,28(08):70.
[13]施振宇,劉鐘,陳文亮,等.中醫(yī)綜合療法防治絕經(jīng)后骨量減少的多中心臨床研究[J].中醫(yī)正骨,2017,29(04):1.
SHI Zhenyu,LIU Zhong,CHEN Wenliang,et al.A multicenter clinical study of complex therapy of traditional Chinese medicine for prevention and treatment of postmenopausal osteopenia[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(03):1.
[14]梁文娜,李西海,李燦東.血清microRNA與絕經(jīng)后骨質(zhì)疏松癥腎虛證的關(guān)系[J].中醫(yī)正骨,2017,29(10):53.
[15]梁文娜,李西海,胡柳,等.二至丸抑制絕經(jīng)后骨質(zhì)疏松大鼠骨代謝紊亂的作用機制研究[J].中醫(yī)正骨,2017,29(11):1.
LIANG Wenna,LI Xihai,HU Liu,et al.Study on mechanism of action of Erzhi Wan(二至丸)in inhibiting bone metabolism disorder in rats with postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(03):1.
[16]楊依然,劉鐘,毛一凡,等.酪蛋白激酶-2相互作用蛋白1基于磷脂酰肌醇3-激酶/蛋白激酶B/哺乳動物雷帕霉素靶蛋白通路參與絕經(jīng)后骨質(zhì)疏松癥發(fā)生發(fā)展過程中細胞自噬的機制[J].中醫(yī)正骨,2018,30(04):59.
[17]曹俊青,鄭劍南,張麟.右歸丸聯(lián)合阿侖膦酸鈉口服治療絕經(jīng)后骨質(zhì)疏松癥腎陽虛證的臨床研究[J].中醫(yī)正骨,2018,30(05):20.
CAO Junqing,ZHENG Jiannan,ZHANG Lin.A clinical study of oral application of Yougui Wan(右歸丸)and alendronate sodium for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(03):20.
[18]李中萬,徐紹俊,楊廣鋼,等.健腎方聯(lián)合碳酸鈣D3咀嚼片(Ⅱ)
治療絕經(jīng)后骨質(zhì)疏松癥腎陽虛證[J].中醫(yī)正骨,2018,30(08):11.
LI Zhongwan,XU Shaojun,YANG Guanggang,et al.Oral application of Jianshen Fang(健腎方)and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(03):11.
[19]趙凡,劉全,吳連國.口服強骨飲聯(lián)合碳酸鈣D3片治療絕經(jīng)后骨質(zhì)疏松癥的臨床研究[J].中醫(yī)正骨,2019,31(04):26.
ZHAO Fan,LIU Quan,WU Lianguo.Oral applications of Qianggu Yin(強骨飲)and calcium carbonate and Vitamin D3 tablets for treatment of postmenopausal osteoporosis:a clinical study[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2019,31(03):26.
[20]史曉林,楊依然,劉鐘,等.基于蛋白質(zhì)組學(xué)方法分析絕經(jīng)后骨質(zhì)疏松癥全血差異蛋白[J].中醫(yī)正骨,2019,31(06):7.
SHI Xiaolin,YANG Yiran,LIU Zhong,et al.Analysis of proteins which are differentially expressed in whole blood of patients with postmenopausal osteoporosis using proteomics approach[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2019,31(03):7.